Mangafodipir Trisodium.
Research-backed compound with potential health benefits. In a hospital, it makes your liver and bile ducts visible on an MRI.
Reviewed March 2026
- Category
- Compound
What Mangafodipir Trisodium is, and what it does.
- Does it work
- No. As a supplement, this is a hard pass. The research is for IV use in critical care situations, not for general health. Don't fall for the hype.
- How much to take
- Zero. Don't take this orally. The established doses are for intravenous use by a doctor. There is no safe or effective oral dose.
- Time to feel it
- It's given by injection in a hospital, and its effect is on how tissue appears in a scan rather than on how a person feels, so there's no onset to notice.
- The first dose
- Nothing, because you aren't taking this. If you got it via IV for an MRI, you still wouldn't 'feel' it kick in.
- With regular use
- Unknown and unsafe for oral use. Long-term self-dosing could lead to manganese accumulation and toxicity, which can cause serious neurological problems.
- How well tolerated
- Not safe for self-administration. It's designed for single-dose IV use under medical supervision. The risks of oral use are completely unknown.
- How it feels
- Like nothing. It's a diagnostic tool that works at a cellular level. It is not designed to be 'felt'.
- The overlooked benefit
- The manganese sits inside a cage built from a vitamin B6 relative. Once the complex breaks up, that metal is handled by ordinary manganese routes and cleared in bile.
5 to 10mg a day is where Mangafodipir Trisodium works.
Source: Prescription drug/MRI contrast agent; not a dietary supplement
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Mangafodipir Trisodium is documented in the library; the clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- contrast enhancement of liver and bile ducts in magnetic resonance imagingRandomised trial
- superoxide dismutase-like activity of the manganese complexIn vitro study
- tissue oxidative stress research in animalsAnimal study
Questions people ask about Mangafodipir Trisodium.
- Can I take this for brain health?
- No. The research is on IV use during strokes. Taking it orally is not the same and isn't proven to do anything except risk manganese toxicity.
- Is it just a special form of manganese?
- Yes, it's manganese attached to a carrier molecule derived from vitamin B6. This helps deliver it to specific tissues, like the liver.
- Where can I buy Mangafodipir?
- You can't, and you shouldn't. It's a prescription drug (Teslascan) used for MRIs. Steer clear of any online sellers claiming to have it.
- Is this better than a regular manganese supplement?
- They are for completely different things. Regular manganese supplements are for dietary shortfalls. This is a targeted IV drug. They are not interchangeable.
- Is it better than other antioxidants?
- We have no idea for oral use. It works differently. For now, stick to proven oral antioxidants like Vitamin C, E, or NAC.
- What are the side effects?
- When used as an IV drug: flushing, headache, or nausea. For oral use: nobody knows for sure, but manganese toxicity is the major concern.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Mangafodipir trisodium is a coordination complex in which one manganese ion sits inside the dipyridoxyl diphosphate (fodipir) ligand. The manganese is the functional centre and the ligand is what keeps it in solution and controls where it goes. Free manganese released after partial dechelation behaves as ordinary manganese in the body. The relationship is structural rather than a supplement pairing.
Aminopolycarboxylate ligands of this class do not hold manganese exclusively; circulating zinc can exchange into the ligand and displace manganese, a transmetallation that is standard chemistry for chelates of this type. The displaced manganese then distributes as free ion while zinc leaves the body bound to the ligand. This is a competition for the ligand, not a nutritional pairing, and it is one reason zinc excretion is watched with chelating agents generally.
The fodipir ligand is a bis-pyridoxyl ethylenediamine diphosphate, meaning its backbone is two vitamin B6 derived rings joined through a diamine. Dephosphorylation of the ligand yields pyridoxal-type species that sit in the same chemical family as vitamin B6 metabolites. That relationship is structural and metabolic rather than a supplement combination, and it explains why the compound is discussed alongside B6 chemistry.
Ligands carrying multiple carboxylate and phosphate donor groups bind divalent cations broadly, and calcium is the most abundant divalent cation in plasma. Any binding of calcium is weak next to manganese and zinc, so the practical share of ligand it takes is small. The point matters mainly for how the complex behaves in a mixed-ion solution rather than for any nutritional effect.
Transition metals including iron can compete for a polyaminocarboxylate binding pocket, though in plasma most iron is already held by transferrin and is not freely available for exchange. The competition is therefore chemically real and biologically limited. It belongs in the same discussion as zinc transmetallation rather than as a separate pairing.
Nothing specific on file for Mangafodipir Trisodium. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Mangafodipir Trisodium actually does.
Mangafodipir trisodium is a one-to-one coordination complex of manganese with dipyridoxyl diphosphate, formulated as the trisodium salt so that it dissolves for parenteral administration.
The manganese centre is paramagnetic, which is the physical property that makes the complex behave as a contrast agent in magnetic resonance imaging; the effect is on water proton relaxation, not on any tissue process.
After administration the complex undergoes dephosphorylation and partial dechelation, releasing manganese that is taken up by hepatocytes and other tissues through ordinary manganese handling routes and cleared largely in bile.
Where Mangafodipir Trisodium comes from.
It is made in a pharmaceutical plant, not grown or extracted. Chemists build a cage-shaped molecule from a vitamin B6 relative, lock a manganese atom inside it, add sodium to balance the charge, and fill the sterile liquid for injection.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
The ligand backbone starts from pyridoxal or pyridoxine chemistry, the same vitamin B6 ring system, joined through an ethylenediamine core.
The diamine is alkylated to give the dipyridoxyl diacetate framework, and the 5,5' hydroxymethyl positions are phosphorylated to give fodipir.
A manganese salt is combined with the ligand in controlled stoichiometry so the manganese sits in the chelate pocket rather than remaining free in solution.
Sodium counter-ions are added to give the trisodium salt, and the ratio of chelated to free metal is fixed as part of the specification.
The complex is purified and the residual free manganese and free ligand are controlled to pharmacopoeial limits.
The finished article is a sterile, buffered aqueous solution filled for parenteral administration.
The forms it comes in.
The essence, in one line each.
- Review notes that mangafodipir trisodium releases manganese that the liver clears on first pass, and that repeated manganese loading can accumulate in brain tissue because import across the blood-brain barrier is not matched by any evidence of export.Review. Crossgrove et al., 2004 (NMR in biomedicine). PMID 15617053 ↗
These are the studies our verdict leans on, chosen from the 7 we read for Mangafodipir Trisodium. The full linked list is below.
The studies, linked.
2 sources behind our Mangafodipir Trisodium verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialManganese-Enhanced Magnetic Resonance Imaging: Applications in CardiomyopathyClinicalTrials.gov ↗90 participants · Completed
- Clinical trialA Phase 2 Proof-of-Concept Clinical Trial to Quantify Myocardial Manganese Uptake Rate by Cardiovascular Magnetic Resonance Imaging Following Mangafodipir Trisodium Administration in Healthy Volunteers and Heart Failure Patients With Preserved Ejection Fraction Caused by Hypertrophic Cardiomyopathy or Cardiac Amyloidosis.ClinicalTrials.gov ↗PHASE2 · 44 participants · Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.